Streetbeat News

KAPA

Kairos Pharma, Ltd.

Industry

Biotechnology

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

EF Hutton has initiated coverage on Kairos Pharma with a Buy rating and set a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:18 pm

Several healthcare stocks experienced significant price movements in Monday's after-market session. Vincerx Pharma, Oragenics, Avidity Biosciences, Tivic Health Systems, Verrica Pharmaceuticals, and Immunome saw gains, while LogicMark, Trevena, Soligenix, Mainz Biomed, Kairos Pharma, and Cue Biopharma experienced declines.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 8:31 pm

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include Carmell (CTCX) with a 31% increase and Processa Pharma (PCSA) with a 30.07% rise. Among the losers, Soligenix (SNGX) saw an 8.6% decline, and Inspire Veterinary (IVP) fell by 6.34%.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 8:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Eterna Therapeutics, ModivCare, Cardio Diagnostics, Autolus Therapeutics, Beyond Air, and Meihua Intl Medical Techs saw notable gains. Conversely, Humana, Carmell, Tivic Health Systems, Kairos Pharma, IGM Biosciences, and Silexion Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

Several health care stocks experienced significant price movements during Thursday's intraday session. Notable gainers included Pasithea Therapeutics, Telesis Bio, and Adaptive Biotechnologies, while Inventiva and Theriva Biologics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:31 pm

Kairos Pharma's stock is rising following its partnership with PreCheck Health Services to develop biomarkers aimed at overcoming cancer drug resistance in prostate and lung cancer.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:28 pm

Kairos Pharma has partnered with PreCheck Health Services to develop biomarkers aimed at targeting cancer drug resistance in prostate and lung cancer patients. This collaboration seeks to enhance patient selection for Kairos Pharma's ENV105 therapy.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:21 pm

Shares of Kairos Pharma were halted due to a circuit breaker triggered by a significant downside movement. This indicates a sharp decline in the stock price, which could be due to various factors such as negative news or market conditions.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:09 pm

Kairos Pharma's IPO shares opened for trading at $3.75 per share, slightly below the IPO price of $4 per share. The IPO involved 1.55 million shares.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:08 pm

Kairos Pharma has priced its IPO at $4.00 per share, raising $6.2 million. The company will trade on the NYSE American under the symbol 'KAPA' starting September 16, 2024. The funds will support clinical trials for lung and prostate cancer, as well as preclinical candidates.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.